Defining genetic risk factors for scleroderma-associated interstitial lung diseaseIRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease

被引:0
|
作者
Carmel J. W. Stock
Angelo De Lauretis
Dina Visca
Cecile Daccord
Maria Kokosi
Vasilis Kouranos
George Margaritopoulos
Peter M. George
Philip L. Molyneaux
Svetlana Nihtyanova
Felix Chua
Toby M. Maher
Voon Ong
David J. Abraham
Christopher P. Denton
Athol U. Wells
Louise V. Wain
Elisabetta A. Renzoni
机构
[1] Royal Brompton and Harefield NHS Foundation Trust,Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London
[2] Ospedale Guido Salvini,Unita’ Operativa Malattie Respiratorie
[3] Istituti Clinici Scientifici Maugeri,Division of Pulmonary Rehabilitation
[4] IRCCS,Division of Respiratory Medicine
[5] Lausanne University Hospital (CHUV),Centre for Rheumatology and Connective Tissue Diseases
[6] Royal Free and University College Medical School,Department of Health Sciences
[7] University of Leicester,National Institute for Health Research
[8] Leicester Respiratory Biomedical Research Centre,undefined
[9] Glenfield Hospital,undefined
来源
Clinical Rheumatology | 2020年 / 39卷
关键词
Genetic association; Genetics; SSc-ILD;
D O I
暂无
中图分类号
学科分类号
摘要
Although several genetic associations with scleroderma (SSc) are defined, very little is known on genetic susceptibility to SSc-associated interstitial lung disease (SSc-ILD). A number of common polymorphisms have been associated with SSc-ILD, but most have not been replicated in separate populations. Four SNPs in IRF5, and one in each of STAT4, CD226 and IRAK1, selected as having been previously the most consistently associated with SSc-ILD, were genotyped in 612 SSc patients, of European descent, of whom 394 had ILD. The control population (n = 503) comprised individuals of European descent from the 1000 Genomes Project. After Bonferroni correction, two of the IRF5 SNPs, rs2004640 (OR (95% CI)1.30 (1.10–1.54), pcorr = 0.015) and rs10488631 (OR 1.48 (1.14–1.92), pcorr = 0.022), and the STAT4 SNP rs7574865 (OR 1.43 (1.18–1.73), pcorr = 0.0015) were significantly associated with SSc compared with controls. However, none of the SNPs were significantly different between patients with SSc-ILD and controls. Two SNPs in IRF5, rs10488631 (OR 1.72 (1.24–2.39), pcorr = 0.0098), and rs2004640 (OR 1.39 (1.11–1.75), pcorr = 0.03), showed a significant difference in allele frequency between controls and patients without ILD, as did STAT4 rs7574865 (OR 1.86 (1.45–2.38), pcorr = 6.6 × 10−6). A significant difference between SSc with and without ILD was only observed for STAT4 rs7574865, being less frequent in patients with ILD (OR 0.66 (0.51–0.85), pcorr = 0.0084). In conclusion, IRF5 rs2004640 and rs10488631, and STAT4 rs7574865 were significantly associated with SSc as a whole. Only STAT4 rs7574865 showed a significant difference in allele frequency in SSc-ILD, with the T allele being protective against ILD.Key points• We confirm the associations of the IRF5 SNPs rs2004640 and rs10488631, and the STAT4 SNP rs7574865, with SSc as a whole.• None of the tested SNPs were risk factors for SSc-ILD specifically.• The STAT4 rs7574865 T allele was protective against the development of lung fibrosis in SSc patients.• Further work is required to understand the genetic basis of lung fibrosis in association with scleroderma.
引用
下载
收藏
页码:1173 / 1179
页数:6
相关论文
共 50 条
  • [41] Living Donor Lobar Lung Transplantation For Scleroderma-Associated Usual Interstitial Pneumonia: 8 Years And Counting
    Lane-Laratta, C.
    Jackson, K.
    Puttagunta, L.
    Mullen, J.
    Lien, D.
    Weinkauf, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [42] THE LAMININ A4 IS EXPRESSED IN INTERSTITIAL LUNG DISEASE ASSOCIATED WITH LUPUS AND SCLERODERMA
    Kielhauser, S.
    Stacher, E.
    Fuerst, F.
    Kremser, M.
    Stradner, M.
    Popper, H.
    Graninger, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70
  • [43] Chitinase 1 Is a Biomarker for and Therapeutic Target in Scleroderma-Associated Interstitial Lung Disease That Augments TGF-β1 Signaling
    Lee, Chun Geun
    Herzog, Erica L.
    Ahangari, Farida
    Zhou, Yang
    Gulati, Mridu
    Lee, Chang-Min
    Peng, Xueyan
    Feghali-BostwickO, Carol
    Jimenez, Sergio A.
    Varga, John
    Elias, Jack A.
    JOURNAL OF IMMUNOLOGY, 2012, 189 (05): : 2635 - 2644
  • [44] Can home rehabilitation impact impulse oscillometry and lung ultrasound findings in patients with scleroderma-associated interstitial lung disease? A pilot study
    de Alegria, Samantha Gomes
    Litrento, Patricia Frascari
    Farias, Iasmim de Oliveira
    Mafort, Thiago Thomaz
    Lopes, Agnaldo Jose
    BMC RESEARCH NOTES, 2022, 15 (01)
  • [45] Can home rehabilitation impact impulse oscillometry and lung ultrasound findings in patients with scleroderma-associated interstitial lung disease? A pilot study
    Samantha Gomes de Alegria
    Patrícia Frascari Litrento
    Iasmim de Oliveira Farias
    Thiago Thomaz Mafort
    Agnaldo José Lopes
    BMC Research Notes, 15
  • [46] Mycophenolate in scleroderma-associated interstitial lung disease: Real-world data from rheumatology and pulmonology clinics in South Asia
    Janardana, Ramya
    Irodi, Aparna
    Chebbi, Pramod P.
    Goel, Ruchika
    Vimala, Leena R.
    Padiyar, Shivraj
    Peediyakal, Anoof
    Mathew, John
    Nair, Aswin
    Christopher, Devasahayam J.
    Danda, Debashish
    JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2021, 6 (03) : 271 - 276
  • [47] Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
    Silver, Rick
    Atanelishvili, Ilia
    Akter, Tanjina
    Kajdasz, Kelley
    Wilson, Dulaney
    Nietert, Paul J.
    Huggins, J. Terrill
    Highland, Kristin B.
    Bogatkevich, Galina S.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [48] Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
    Silver, R.
    Atanelishvili, I.
    Akter, T.
    Kajdasz, K.
    Wilson, D.
    Nietert, P.
    Huggins, J. T.
    Highland, K. B.
    Bogatkevich, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [49] An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
    Khanna, Dinesh
    Albera, Carlo
    Fischer, Aryeh
    Khalidi, Nader
    Raghu, Ganesh
    Chung, Lorinda
    Chen, Dan
    Schiopu, Elena
    Tagliaferri, Margit
    Seibold, James R.
    Gorina, Eduard
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (09) : 1672 - 1679
  • [50] A Case Report of Living-donor Lobar Lung Transplantation for Scleroderma-associated Usual Interstitial Pneumonia: Eight Years and Counting
    Laratta, C.
    Lien, D.
    Puttagunta, L.
    Jackson, K.
    Mullen, J.
    Kapasi, A.
    Weinkauf, J.
    TRANSPLANTATION PROCEEDINGS, 2015, 47 (01) : 190 - 193